Quarterly ResultAug 11, 2026, 08:16 AM
Theriva Biologics Q2 Net Loss $(3.2M); VIRAGE2 Study Doses First Patients
AI Summary
Theriva Biologics reported a significant reduction in its net loss for the second quarter of 2026, with a net loss of $(3.2) million, down from $(13.1) million in the prior year. The company also achieved key operational milestones, including dosing the first patients in its VIRAGE2 Phase 2a clinical study for metastatic pancreatic ductal adenocarcinoma (PDAC) and completing the design for a proposed Phase 2/3 clinical trial for retinoblastoma. Cash and cash equivalents stood at $11.3 million as of June 30, 2026, providing a cash runway into Q1 2027.
Key Highlights
- Q2 2026 Net Loss: $(3.2) million, significantly reduced from $(13.1) million in Q2 2025.
- Q2 2026 Net Loss Per Share: $(0.07), improved from $(1.93) in Q2 2025.
- General and administrative expenses decreased 82% to $2.0 million in Q2 2026.
- Research and development expenses decreased 35% to $1.3 million in Q2 2026.
- Cash and cash equivalents totaled $11.3 million as of June 30, 2026, with runway into Q1 2027.
- First patients dosed in the VIRAGE2 Phase 2a clinical study for metastatic pancreatic cancer.
- Completed design for a proposed Phase 2/3 retinoblastoma trial; FDA discussion planned for Q3 2026.
- Phase 1 clinical trial results for VCN-01 in HNSCC published in Clinical Cancer Research.
Price Impact
More from TOVX